A new concept in colonic drug targeting: A combined pH-responsive and bacterially-triggered drug delivery technology

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 7, 2008, Pages 911-916

  Ibekwe, V C ^a   Khela, M K ^b   Evans, D F ^b   Basit, A W ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMER; POLYSACCHARIDE;

ARTICLE; DIET RESTRICTION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENTERITIS; FEEDING; GAMMA SCINTIGRAPHY; HUMAN; HUMAN EXPERIMENT; ILEOCECAL VALVE; INTESTINE FLORA; ISOTOPE LABELING; NORMAL HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; STOMACH EMPTYING; STOMACH PH; TABLET DISINTEGRATION;

ADULT; ANALYSIS OF VARIANCE; COLON, ASCENDING; DRUG DELIVERY SYSTEMS; ENTEROBACTERIACEAE; FOOD; GASTROINTESTINAL TRANSIT; HUMANS; HYDROGEN-ION CONCENTRATION; ISOTOPE LABELING; MALE; TABLETS, ENTERIC-COATED;

EID: 50849113050     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03810.x     Document Type: Article

References (28)

1. Frieri G, Pimpo MT, Andreoli A, et al. Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine. Aliment Pharmacol Ther 1999 13: 577 82.
2. Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev 2005 57: 267 79.
3. Cohen RD. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006 24: 465 74.
4. Minko T. Drug targeting to the colon with lectins and neoglycoconjugates. Adv Drug Deliv Rev 2004 56: 491 509.
5. McConnell EL, Basit AW, Murdan S. Colonic antigen administration induces significantly higher humoral levels of colonic and vaginal IgA, and serum IgG compared to oral administration. Vaccine 2008 26: 639 46.
6. Mackay M, Phillips J, Hastewell J. Peptide drug delivery: colonic and rectal absorption. Adv Drug Deliv Rev 2004 1997 28: 253 73.
7. Basit AW. Advances in colonic drug delivery. Drugs 2005 65: 1991 2007.
8. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988 29: 1035 41.
9. Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther 1989 3: 605 13.
10. Simon GL, Gorbach SL. The human intestinal microflora. Dig Dis Sci 1986 31 (9 Suppl 147S 62S.
11. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005 308: 1635 8.
12. Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 2008 doi :.
13. Scheline RR. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev 1973 25: 451 523.
14. McConnell EL, Murdan S, Basit AW. An investigation into the digestion of chitosan (noncrosslinked and crosslinked) by human colonic bacteria. J Pharm Sci 2008 97: 3820 9.
15. 13C] glucose microspheres as a model for drug delivery to the colon. J Control Rel 1996 40: 123 31.
16. Tuleu C, Basit AW, Waddington WA, Ell PJ, Newton JM. Colonic delivery of 4-aminosalicylic acid using amylose-ethylcellulose-coated hydroxypropylmethylcellulose capsules. Aliment Pharmacol Ther 2002 16: 1771 9.
17. Ibekwe VC, Fadda HM, McConnell EL, Khela MK, Evans DF, Basit AW. Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res 2008 25: 1828 35.
18. Ibekwe VC, Liu F, Fadda HM, et al. An investigation into the in vivo performance variability of pH responsive polymers for ileo-colonic drug delivery using gamma scintigraphy in humans. J Pharm Sci 2006 95: 2760 6.
19. Podczeck F, Course NJ, Newton JM. Determination of the gastric emptying of solid dosage forms using gamma-scintigraphy: a problem of image timing and mathematical analysis. Eur J Nucl Med 1999 26: 373 8.
20. Code CF, Marlett JA. The interdigestive myo-electric complex of the stomach and small bowel of dogs. J Physiol 1975 246: 289 309.
21. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007 369: 1641 57.
22. Keller J, Layer P. Human pancreatic exocrine response to nutrients in health and disease. Gut 2005 54 (Suppl 6 vi1 28.
23. Safdi AV. Determination of mesalazine in whole or partial mesalamine delayed-release tablets recovered from fecal samples of healthy volunteers. Am J Gastroenterol 2005 100: S159.
24. Sinha A, Ball BJ, Connor AL, Nightingale J, Wilding IR. Intestinal performance of two mesalamine formulations in patients with active ulcerative colitis as assessed by gamma scintigraphy. Pract Gastroenterol 2003 27: 56 69.
25. McConnell EL, Short MD, Basit AW. An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man. J Control Rel 2008 97: 3820 9.
26. Macfarlane GT, Englyst HN. Starch utilization by the human large intestinal microflora. J Appl Bacteriol 1986 60: 195 201.
27. Gotch F, Nadell J, Edelman IS. Gastrointestinal water and electrolytes. IV The equilibration of deuterium oxide (D2O) in gastrointestinal contents and the proportion of total body water (T.B.W) in the gastrointestinal tract. J Clin Invest 1957 36: 289 96.
28. Cummings JH, Banwell JG, Segal I, Coleman N, Englyst HN, Macfarlane GT. The amount and composition of large bowel contents in man. Gastroenterology 1990 98: A408.